Other - Net, Expense (Income) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Other Revenue, Net									$ 833.7	$ 808.1	$ 788.4
Income related to termination of the exenatide collaboration with Amylin									203.9	0.0	0.0
Interest Expense									185.2	161.2	148.8
Investment Income, Interest									(108.7)	(87.0)	(121.0)
Gains (Losses) on Extinguishment of Debt									0.0	166.7	0.0
Other (income)expense									(195.6)	(341.5)	(368.3)
Nonoperating Income (Expense), Total	$ (15.8)	$ (27.2)	$ (21.2)	$ 149.0	$ (44.7)	$ (86.5)	$ 123.3	$ (92.7)	$ 84.8	$ (100.6)	$ (340.5)